Clinical trial
A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
NCT00428610 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00428610 |
|---|---|
| Title | A Study of Chemotherapy Treatment for Patients With Ovarian Cancer |
| Official title | A Phase 2 Study of LY573636-Sodium as Treatment for Patients With Platinum-Resistant Ovarian Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer |
| Intervention type | Drug |
| Interventions | LY573636-sodium |
| Enrollment | 103 |
| Start date | Feb 1, 2007 |
| Primary completion | Feb 1, 2011 |
| Completion | Jan 1, 2012 |
| First posted | Jan 30, 2007 |
| Last update posted | Apr 19, 2018 |
| Countries | Italy, Russia, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: